Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Recruiting · NCT04803318 · Interventional (participants receive a specific treatment) · Lead sponsor: Second Affiliated Hospital of Guangzhou Medical University
View the official record on ClinicalTrials.gov →Interventions studied
Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
What this trial is about
To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.
Who can take part
Age range
18 Years to 85 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Recurrent/Refractory advanced solid tumors
- Age between 18 and 85 years
- Expected life expectancy is greater than three months
Exclusion criteria
- Benign tumor
- Life expectancy is less than three months
- Serious medical commodities
- others
Where it is running
1 location listed.
- The Second Affiliated Hospital of Guangzhou Medical University - Guangzhou, Guangdong, China